IL313876A - Compositions and methods for targeted delivery to cells - Google Patents

Compositions and methods for targeted delivery to cells

Info

Publication number
IL313876A
IL313876A IL313876A IL31387624A IL313876A IL 313876 A IL313876 A IL 313876A IL 313876 A IL313876 A IL 313876A IL 31387624 A IL31387624 A IL 31387624A IL 313876 A IL313876 A IL 313876A
Authority
IL
Israel
Prior art keywords
compositions
cells
methods
targeted delivery
targeted
Prior art date
Application number
IL313876A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of IL313876A publication Critical patent/IL313876A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL313876A 2021-12-27 2022-12-27 Compositions and methods for targeted delivery to cells IL313876A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163294066P 2021-12-27 2021-12-27
PCT/US2022/082411 WO2023129915A2 (en) 2021-12-27 2022-12-27 Compositions and methods for targeted delivery to cells

Publications (1)

Publication Number Publication Date
IL313876A true IL313876A (en) 2024-08-01

Family

ID=87000245

Family Applications (1)

Application Number Title Priority Date Filing Date
IL313876A IL313876A (en) 2021-12-27 2022-12-27 Compositions and methods for targeted delivery to cells

Country Status (7)

Country Link
EP (1) EP4456921A2 (https=)
JP (1) JP2025500547A (https=)
CN (1) CN118660721A (https=)
AU (1) AU2022425201A1 (https=)
CA (1) CA3242318A1 (https=)
IL (1) IL313876A (https=)
WO (1) WO2023129915A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118001254B (zh) * 2024-04-09 2024-07-26 北京悦康科创医药科技股份有限公司 靶向抗原呈递细胞的脂质组合物及其应用
WO2026062291A1 (en) 2024-09-23 2026-03-26 Aldexchem Kft. Silicon-containing spleen-targeted lnp delivery systems
KR20260043575A (ko) * 2024-09-24 2026-03-31 주식회사 녹십자 선택적 장기 표적 지질을 포함하는 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10383952B2 (en) * 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
CA3103528A1 (en) * 2018-06-19 2019-12-26 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mrna and long nucleic acids
WO2020051223A1 (en) * 2018-09-04 2020-03-12 The Board Of Regents Of The University Of Texas System Compositions and methods for organ specific delivery of nucleic acids

Also Published As

Publication number Publication date
JP2025500547A (ja) 2025-01-09
CN118660721A (zh) 2024-09-17
WO2023129915A3 (en) 2023-08-10
WO2023129915A2 (en) 2023-07-06
EP4456921A2 (en) 2024-11-06
CA3242318A1 (en) 2023-07-06
AU2022425201A1 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
IL313876A (en) Compositions and methods for targeted delivery to cells
GB2613225B (en) Compositions and methods for targeted RNA delivery
IL290862A (en) Preparations and methods for administering nucleic acids to cells
GB2605312B (en) Compositions and methods for delivery of RNA
IL305782A (en) Compositions and methods for targeted delivery to cells
IL221396A (en) Preparations for the Delivery of Oligonucleotides to Liver Cells, and Methods for their Production
CA3250175A1 (en) Agents and Methods for Targeted Cell Administration
PH12014502445A1 (en) Targeted modification of malate dehydrogenase
IL309175A (en) Methods and preparations for targeting PD-L1
BR112015011244A2 (pt) Análogos de compstatina de ação prolongada, método de fabricação e uso dos mesmos, bem como composição de qualidade farmacêutica
PH12013502284A1 (en) Protein-active agent conjugates and method for preparing the same
ZA201008597B (en) Methods and compositions for enhanced delivery of macromolecules
MY156963A (en) Ethanol compositions
GB2608279B (en) Therapeutic cell compositions and methods for manufacture and uses thereof
WO2012167028A9 (en) Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
SG11202107904PA (en) Compositions and methods for stimulating natural killer cells
IN2014DN03298A (https=)
IL221504B (en) Compositions and methods for targeting type 1 interferon producing cells
EP2794879A4 (en) COMPOSITIONS AND METHODS FOR RELEASING BIOLOGICALLY ACTIVE RNA
IL290134A (en) Methods and compositions for reducing immunogenicity using non-depleted b-cell inhibitors
IL288260A (en) Preparations and methods for plant cell culture
GB201821286D0 (en) Compositions and methods for delivery of nucleic acid to plant cells
IL304123A (en) RNA transfer preparations and methods
IL305998A (en) Formulations and methods for targeted systemic delivery to cells
EP3277297A4 (en) Methods and compositions for stimulation of cell proliferation and provision of biologically active mixtures of fgf2 isoforms